23 Sep 2026
Topline announcement of Phase 3 trial results for FUS-MND appear promising
Yesterday, the companies Otsuka and Ionis announced the results of their Phase 3 trial of the genetic therapy, ulefnersen. Ulefnersen targets a rare form of MND…
Read more